申请人:Bayer Aktiengesellschaft
公开号:US04876254A1
公开(公告)日:1989-10-24
For the treatment of circulation disorders, the novel 5-nitro-1,4-dihydropyridines of the formula ##STR1## in which R represents C.sub.6 -C.sub.14 -aryl which can be mono- to pentasubstituted by identical or different substituents from the series comprising halogen, nitro, cyano, C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkylthio, trifluoromethyl, trifluoromethoxy, difluoromethoxy, trifluoromethylthio and benzyl, benzyloxy or benzylthio optionally substituted by nitro, cyano, trifluoromethyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkoxy, or represents a heterocycle from the series pyrryl, thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidyl, quinolyl, benzoxadiazolyl, chromenyl or thiochromenyl optionally mono- to tetrasubstituted by halogen, phenyl or C.sub.1 -C.sub.4 -alkyl or represents straight-chain, branched or cyclic alkyl with up to 14 carbon atoms, and their physiologically acceptable salts.
用于治疗循环障碍的新型5-硝基-1,4-
二氢吡啶,其
化学式为##STR1##其中R代表C.sub.6-C.sub.14-芳基,可以是单-五取代的,取代基可以是相同或不同的卤素、硝基、
氰基、C.sub.1-C.sub.6-烷基、C.sub.1-C.sub.6-烷氧基、C.sub.1-C.sub.6-烷
硫基、三
氟甲基、三
氟甲氧基、二
氟甲氧基、三
氟甲基
硫基和苄基、苄氧基或苄
硫基,可选用硝基、
氰基、三
氟甲基、C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.4-烷氧基进行取代,或者R代表来自于
吡咯基、
噻吩基、
呋喃基、
吡唑基、
咪唑基、
噁唑基、
噻唑基、
吡啶基、
吡嗪基、
嘧啶基、
喹啉基、苯并
噁唑啉基、
香豆酸苯基、
香豆酸苯甲氧基或
香豆酸苯甲
硫基等系列的杂环,可选用卤素、苯基或C.sub.1-C.sub.4-烷基进行单-四取代,或者R代表直链、支链或环状烷基,碳数最多为14,以及其生理上可接受的盐。